How has the acute renal failure (arf) market evolved, and where is it heading next?
The acute renal failure (ARF) market size has grown strongly in recent years. It will grow from $6.09 billion in 2024 to $6.62 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to rising aging population, growing incidence of sepsis, improved diagnostic capabilities, government healthcare initiatives, and rising cases of nephrotoxic medication.
The acute renal failure (ARF)market size is expected to see strong growth in the next few years. It will grow to $9.09 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to expansion of home-based dialysis solutions, emerging markets, development of renal biomarkers, r&d for new therapeutic drugs and, and rising demand for non-invasive diagnostics. Major trends in the forecast period include continuous renal replacement therapy (CRRT) innovations, 3d bioprinting of renal tissue, wearable biosensors, next-generation dialysis machines and nanotechnology-driven drug delivery.
Get Your Free Sample of The Global Acute Renal Failure (ARF) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21083&type=smp
What are the key drivers behind the rapid expansion of the acute renal failure (arf) market?
The increasing prevalence of chronic kidney diseases is expected to propel the growth of the acute renal failure (ARF) market going forward. Chronic kidney disease (CKD) refers to a long-term condition where the kidneys are damaged and can’t filter blood properly. The increasing prevalence of chronic kidney disease (CKD) is due to rising rates of diabetes, hypertension, obesity, aging populations, and lifestyle-related factors worldwide. Acute renal failure, characterized by the sudden loss of kidney function, can act as a significant trigger or exacerbating factor for chronic kidney disease by causing lasting damage to kidney tissues, impairing filtration efficiency, and increasing the risk of progressive, long-term kidney dysfunction when not managed effectively. For instance, in June 2023, according to the report published by Kidney Research UK, a UK-based non-profit organization, currently, approximately 7.2 million people in the UK are living with chronic kidney disease, representing over 10% of the population. Of these, 3.25 million are in the advanced stages of the disease, while an additional 3.9 million are in the early stages. By 2033, the number of individuals affected by chronic kidney disease is projected to rise to 7.61 million. Therefore, the increasing prevalence of chronic kidney diseases is driving growth in the acute renal failure (ARF) market.
What is the segmentation for the acute renal failure (arf) market?
The acute renal failure (ARF) market covered in this report is segmented –
1) By Disease Type: Prerenal Acute Renal Failure, Renal Acute Renal Failure, Postrenal Acute Renal Failure
2) By Drug Type: Diuretics, Vasopressors, Erythropoiesis-Stimulating Agents (ESAS), Phosphate Binders, Calcium and Vitamin D Supplements, Antibiotics, Others Drugs
3) By Route of Administration: Oral, Intravenous
4) By Diagnosis: Computed Tomography (CT) Scan, Kidney Biopsy, Ultrasound
5) By End-Users: Clinics, Hospitals, Home Healthcare, Others End-Users
Subsegments:
1) By Prerenal Acute Renal Failure: Hypovolemia, Decreased Cardiac Output, Renal Artery Stenosis
2) By Renal Acute Renal Failure: Acute Tubular Necrosis, Glomerulonephritis, Interstitial Nephritis
3) By Postrenal Acute Renal Failure: Obstructive Uropathy, Bladder Outlet Obstruction, Kidney Stones
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/acute-renal-failure-arf-global-market-report
Who are the most influential companies in the acute renal failure (arf) market?
Major companies operating in the acute renal failure (ARF) market are Pfizer Inc., Novartis AG, LG Chem Ltd., Medtronic plc, Fresenius Medical Care AG & Co. KGaA, Asahi Kasei Corporation, Baxter International Inc., Astellas Pharma Inc., Syensqo, Dr. Reddy’s Laboratories Limited, Zydus Lifesciences Limited, NIKKISO Co., Ltd., Quark Pharmaceuticals Inc., NIPRO Corporation, Alloksys Life Sciences B.V., AM-Pharma B.V., Sentien Biotechnologies, MediBeacon LLC, Angion Biomedica Corp., Atox Bio Ltd.
What are the most influential trends expected to drive the acute renal failure (arf) market forward?
Major companies operating in the acute renal failure (ARF) market are focusing on obtaining regulatory approvals for drugs to expand their reach and strengthen their position in the treatment of severe acute kidney injury (AKI). Regulatory approvals involve formal authorization from governmental or regulatory bodies for the marketing and public use of drugs, medical devices, or treatments. For instance, in February 2024, CalciMedica., a US-based clinical-stage biopharmaceutical company, received FDA approval for an IND application for a Phase 2 trial of Auxora to evaluate Auxora’s efficacy in treating severe acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF), a condition characterized by a high mortality rate. The KOURAGE trial is a randomized, double-blind, placebo-controlled study designed to enroll approximately 150 patients with Stage 2 and 3 acute kidney injury (AKI) who also have acute hypoxemic respiratory failure (AHRF), assessing the efficacy of Auxora over five daily doses by evaluating the number of days alive without the need for ventilators or dialysis up to 30 days post-treatment.
What are the major regional insights for the acute renal failure (arf) market, and which region holds the top position?
North America was the largest region in the acute renal failure (ARF) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute renal failure (ARF) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Acute Renal Failure (ARF) Market Report 2025 Offer?
The acute renal failure (arf) market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Acute renal failure (ARF), also known as acute kidney injury (AKI), refers to a sudden and rapid decline in kidney function over a period of hours or days. Acute renal failure is treated through various methods, including medication, fluid management, and dialysis, to help restore kidney function and prevent further complications.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21083
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
